Rosiglitazone Maleate
PPARĪ³ agonist / Prototypical TZD antidiabetic agent. Potent and selective PPARĪ³ agonist (Kd=43 nM).1,2 Clinically useful antihyperglycemc agent.3 Induces a brown fat gene program in subcutaneous white adipose tissue via activation of the PRDM16 protein.4 Induces differentiation of pluripotent stem cells into adipocytes.5
Biochemicals & reagents
155141-29-0
Avandia; BRL49653
1) Cantello et al. (1994), [[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents; J. Med. Chem., 37 3977 2) Lehmann et al. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARgamma); J.Biol.Chem., 270 12953 3) Wilson et al. (1996), The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones; J. Med. Chem., 39 665 4) Haruya et al. (2012), PPARgamma agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein; Cell Metab., 15 395 5) Ruiz-Ojeda et al. (2016), Cell Models and their Application for Studying Adipogenic Differentiation in Relation to Obesity: A Review; Int. J. Mol. Sci., 17 E1040
RT
TARGET: Transcription factor -- PATHWAY: PPAR; Fatty acid metabolism; Transcription; Ferroptosis -- RESEARCH AREA: Stem cells; Cell death -- DISEASE AREA: Diabetes; InflammationCancer; Obesity